1
|
Glutathione S-transferase gene polymorphisms and risk of nasal or colorectal polyposis. Biosci Rep 2019; 39:BSR20181226. [PMID: 30617052 PMCID: PMC6350046 DOI: 10.1042/bsr20181226] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2018] [Revised: 12/17/2018] [Accepted: 01/02/2019] [Indexed: 12/30/2022] Open
Abstract
We observed inconsistent conclusions regarding the genetic role of glutathione S-transferase gene polymorphisms, including glutathione S-transferase M1 (GSTM1), glutathione S-transferase T1 (GSTT1) present/null, and glutathione S-transferase pi (GSTP1) Ile105Val polymorphisms, in the susceptibility to nasal or colorectal polyposis (NP or CP). Thus, we aimed to perform a meta-analysis to comprehensively evaluate this association by applying Stata/SE software. After the heterogeneity assumption, Mantel-Haenszel statistics were used to obtain the odds ratio (OR), 95% confidence interval (95% CI) and P-value of the association test (PA ). We obtained a total of 235 articles by searching online databases. After screening, ten eligible case-control studies were finally enrolled in our meta-analysis. For the meta-analysis of the GSTT1 gene under present versus null, we observed a decreased risk of NP [OR = 0.65; PA =0.018], but not CP. In addition, we did not detect any evident association between the GSTM1 present/null polymorphism and NP or CP risk. For the meta-analysis of the GSTP1 Ile105Val polymorphism, compared with controls, an increased risk of NP cases was detected under the models of Val versus Ile (OR = 1.36; PA =0.027), Ile/Val versus Ile/Ile (OR = 1.70; PA =0.011) and Ile/Val+Val/Val versus Ile/Ile (OR = 1.65; PA =0.010). In conclusion, the null genotype of the GSTT1 polymorphism may be linked to an increased susceptibility to NP, whereas the Ile/Val genotype of the GSTP1 Ile105Val polymorphism may be associated with a decreased risk of NP.
Collapse
|
2
|
Liu J, Ding D, Wang X, Chen Y, Li R, Zhang Y, Luo R. N-acetyltransferase polymorphism and risk of colorectal adenoma and cancer: a pooled analysis of variations from 59 studies. PLoS One 2012; 7:e42797. [PMID: 22905173 PMCID: PMC3419224 DOI: 10.1371/journal.pone.0042797] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2012] [Accepted: 07/11/2012] [Indexed: 11/25/2022] Open
Abstract
BACKGROUND There have been an increasing number of studies with evidence suggesting that the N-acetyltransferase 1 (NAT1) and N-acetyltransferase 2 (NAT2) genotypes may be implicated in the development of colorectal cancer (CRC) and colorectal adenoma (CRA). So far the published data on this association has remained controversial, however. We performed a meta-analysis of case-cohort and case-control studies using a subset of the published data, with an aim to derive a better understanding of the underlying relationship. METHODS/PRINCIPAL FINDINGS A literature search was performed using Medline database for relevant studies published through October 31, 2011. A total of 39 publications were selected for this meta-analysis, including 11,724 cases and 16,215 controls for CRC, and 3,701 cases and 5,149 controls for CRA. In our pooled analysis of all these studies, the results of our meta-analysis suggested that the NAT1 genotype was not significantly associated with an elevated CRC risk (OR 0.99, 95% CI 0.91-1.07). We also found that individuals with the rapid NAT2 genotype did have an elevated risk of CRC (OR 1.07, 95% CI 1.01-1.13). There was no evidence for an association between the NAT1 and 2 rapid genotype and an elevated CRA risk (NAT1: OR 1.14, 95% CI 0.99-1.29; NAT2: OR 0.94, 95% CI 0.86-1.03). CONCLUSION This meta-analysis suggests that individuals with NAT2 genotype had an elevated risk of CRC. There was no evidence for the association between NAT1 and 2 rapid genotype and CRA risk.
Collapse
Affiliation(s)
- Jinxin Liu
- Department of Oncology, Nanfang Hospital, Southern Medical University, GuangZhou, China
- Department of Oncology, Longgang District Central Hospital of ShenZhen, ShenZhen, China
| | - Dapeng Ding
- Institute of Genetic Engineering, Southern Medical University, Guangzhou, China
| | - Xiaoxue Wang
- Department of Proctology, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
| | - Yizhi Chen
- Department of Health Records, Longgang District Central Hospital of ShenZhen, ShenZhen, China
| | - Rong Li
- Department of Oncology, Nanfang Hospital, Southern Medical University, GuangZhou, China
| | - Ying Zhang
- College of Pharmacy, Jinan University, Guangzhou, China
| | - Rongcheng Luo
- Department of Oncology, Nanfang Hospital, Southern Medical University, GuangZhou, China
| |
Collapse
|
3
|
Copy number variants in pharmacogenetic genes. Trends Mol Med 2011; 17:244-51. [PMID: 21388883 DOI: 10.1016/j.molmed.2011.01.007] [Citation(s) in RCA: 74] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2010] [Revised: 01/14/2011] [Accepted: 01/14/2011] [Indexed: 01/07/2023]
Abstract
Variation in drug efficacy and toxicity remains an important clinical concern. Presently, single nucleotide polymorphisms (SNPs) only explain a portion of this problem, even in situations where the pharmacological trait is clearly heritable. The Human CNV Project identified copy number variations (CNVs) across approximately 12% of the human genome, and these CNVs were considered causes of diseases. Although the contribution of CNVs to the pathogenesis of many common diseases is questionable, CNVs play a clear role in drug-related genes by altering drug metabolizing and drug response. In this review, we provide a comprehensive evaluation of the clinical relevance of CNVs to drug efficacy, toxicity, and disease prevalence in world populations, and discuss the implication of using CNVs as a diagnostic tool in clinical intervention.
Collapse
|
4
|
Glutathione S-transferase M1 polymorphism and sporadic colorectal cancer risk: An updating meta-analysis and HuGE review of 36 case-control studies. Ann Epidemiol 2010; 20:108-21. [PMID: 20123161 DOI: 10.1016/j.annepidem.2009.10.003] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2009] [Revised: 10/19/2009] [Accepted: 10/21/2009] [Indexed: 11/20/2022]
Abstract
PURPOSE Sporadic colorectal cancer (CRC) is considered to be a multifactorial disease, in which multiple exposures to endogenous factors interact with individual genetic background in a complex manner, resulting in modulation of the risk. The glutathione S-transferase M1 gene (GSTM1) is a particularly attractive candidate for CRC susceptibility because it codes an enzyme involved in the metabolism of environmental carcinogens. However, the epidemiological findings have been inconsistent. METHODS To evaluate this association, we performed an extensive meta-analysis of 36 case-control studies (including 10,009 cases and 15,070 controls). RESULTS Overall, the combined data showed that GSTM1 deficiency is associated with a marginal effect on CRC risk (odds ratio [OR] = 1.13; 95% confidence interval [CI]: 1.03-1.23; P for heterogeneity <0.001). When stratified by race and tumor site, significant results were only observed in Caucasians (OR = 1.14, 95% CI: 1.01-1.27; P for heterogeneity <0.001), whereas no increased risk was detected in other subgroups. CONCLUSIONS The findings of our study support the suggestion that GSTM1 polymorphism is associated with an increased risk of CRC, especially in the Caucasian population. Further investigation into the association between GSTM1 polymorphism and the risk of CRC is warranted and should include larger sample sizes and other genetic polymorphisms in metabolism of environmental carcinogens.
Collapse
|
5
|
Berkhout M, Roelofs HMJ, te Morsche RHM, Dekker E, van Krieken JHJM, Nagengast FM, Peters WHM. Detoxification enzyme polymorphisms are not involved in duodenal adenomatosis in familial adenomatous polyposis. Br J Surg 2007; 95:499-505. [DOI: 10.1002/bjs.6027] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Abstract
Background
Patients with familial adenomatous polyposis (FAP) are at high risk of developing duodenal adenomas and carcinomas. Besides germline mutations in the adenomatous polyposis coli (APC) gene, additional factors may influence the age of onset and number of duodenal adenomas. This study compared the genotype distributions of duodenal detoxification enzyme isoforms in patients with FAP and controls.
Methods
The study included 85 patients with FAP and 218 healthy age- and sex-matched controls. Genotyping of all participants using polymerase chain reaction was performed to detect polymorphisms in isoforms of uridine 5′-diphosphate glucuronosyltransferases (UGTs) and glutathione S-transferases (GSTs): UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A10, UGT2B4, UGT2B7, UGT2B15, GSTA1, GSTP1, GSTM1 and GSTT1.
Results
The variant genotypes of UGT1A3 were less common in patients with FAP than in controls (odds ratio 0·39 (95 per cent confidence interval 0·22 to 0·67)). There were no associations between FAP and the other polymorphic genes. The polymorphisms investigated had no predictive value for the severity of duodenal adenomatosis in patients with FAP.
Conclusion
Although the variant genotypes of UGT1A3 were less common in patients with FAP than in those without, this did not modulate the severity of duodenal adenomatosis.
Collapse
Affiliation(s)
- M Berkhout
- Department of Gastroenterology, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands
| | - H M J Roelofs
- Department of Gastroenterology, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands
| | - R H M te Morsche
- Department of Gastroenterology, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands
| | - E Dekker
- Department of Gastroenterology, Academic Medical Centre, Amsterdam, The Netherlands
| | - J H J M van Krieken
- Department of Pathology, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands
| | - F M Nagengast
- Department of Gastroenterology, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands
| | - W H M Peters
- Department of Gastroenterology, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands
| |
Collapse
|
6
|
Pistorius S, Goergens H, Engel C, Plaschke J, Krueger S, Hoehl R, Saeger HD, Schackert HK. N-Acetyltransferase (NAT) 2 acetylator status and age of tumour onset in patients with sporadic and familial, microsatellite stable (MSS) colorectal cancer. Int J Colorectal Dis 2007; 22:137-43. [PMID: 16896994 DOI: 10.1007/s00384-006-0171-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 06/01/2006] [Indexed: 02/04/2023]
Abstract
INTRODUCTION N-Acetyltransferase (NAT) 2 is an important enzyme involved in the metabolism of different xenobiotics, including potential carcinogens. Allelic variants of the NAT2 gene are determined by a pattern of single nucleotide polymorphisms (SNPs) resulting in slow (SA), intermediate (IA) or rapid acetylator (RA) phenotypes and causing the individual differences in the NAT2 metabolic capacity. To clarify the potential modifying role of the NAT2 acetylator status in microsatellite stable (MSS) colorectal cancer (CRC), we studied 140 patients with sporadic CRC (group 1) and 69 patients with CRC who met at least one criterion of the revised Bethesda guidelines (group 2). OBSERVATIONS We did not observe any significant difference in the NAT2 acetylator status frequency between patients in both groups and 100 healthy controls (P=0.486). Regardless of a younger median age of tumour onset (AO) of 41 years in group 2 patients compared to 64 years in group 1 patients, no significant difference in AO was found between RA and SA status patients in both groups. The median AO in group 1 was 65 years in patients with RA and 63 years with SA status (P=0.065). The median AO in group 2 was 40 years in patients with RA and 42 years with SA status (P=0.814). Multivariate Cox regression analysis revealed that neither the NAT2 acetylator status (P=0.064 and 0.810, respectively) nor the gender (P=0.165 and 0.918, respectively) was a risk factor for the AO in both groups. These data do not support the hypothesis that the NAT2 acetylatorship acts as a modifying factor on the AO in sporadic and familial, microsatellite stable CRC.
Collapse
Affiliation(s)
- Steffen Pistorius
- Department of Visceral, Thoracic and Vascular Surgery, University of Technology Dresden, Fetscherstr. 74, 01307 Dresden, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Zogopoulos G, Gallinger S. Modifiers of risk in familial adenomatous polyposis. CURRENT COLORECTAL CANCER REPORTS 2006. [DOI: 10.1007/s11888-006-0021-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
8
|
Friederich P, Berkhout M, Roelofs HMJ, van Goor H, van Krieken JHJM, Peters WHM, Nagengast FM. Decreased levels of mucosal detoxification enzymes in the pouch of patients with familial adenomatous polyposis. Br J Surg 2006; 93:1108-14. [PMID: 16804871 DOI: 10.1002/bjs.5348] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
BACKGROUND Adenomas can develop in the pouch after colectomy with ileal pouch-anal anastomosis (IPAA) in patients with familial adenomatous polyposis (FAP). Glutathione S-transferases (GSTs) have a protective role in carcinogenesis. GST activity is much higher in the ileum than in the colon. The present study examined the hypothesis that the protective capacity of GSTs may be lowered as a result of colonic metaplasia of the ileal pouch. METHODS Levels of GSTs, glutathione and cysteine, and the degree of inflammation and colonic metaplasia were quantified in biopsies from the pouch and afferent loop of 26 patients with FAP. RESULTS GST enzyme activity, and levels of GST alpha, glutathione and cysteine in the pouch were significantly lower than those in the afferent loop (308 versus 398 nmol per min per mg protein (P<0.001), 4604 versus 5286 ng per mg protein (P=0.010), 27.1 versus 34.8 nmol per mg protein (P=0.023) and 0 versus 4.8 nmol per mg protein (P=0.009) respectively). No correlation was found between inflammation or colonic metaplasia of the pouch and GST enzyme activity in the pouch. CONCLUSION After IPAA, GST detoxification activity in the pouch is significantly lower than that in the afferent ileal loop, which may promote tumorigenesis.
Collapse
Affiliation(s)
- P Friederich
- Department of Gastroenterology, Radboud University Medical Centre, Nijmegen, The Netherlands
| | | | | | | | | | | | | |
Collapse
|
9
|
Pistorius S, Görgens H, Krüger S, Engel C, Mangold E, Pagenstecher C, Holinski-Feder E, Moeslein G, von Knebel Doeberitz M, Rüschoff J, Karner-Hanusch J, Saeger HD, Schackert HK. N-acetyltransferase (NAT) 2 acetylator status and age of onset in patients with hereditary nonpolyposis colorectal cancer (HNPCC). Cancer Lett 2005; 241:150-7. [PMID: 16337339 DOI: 10.1016/j.canlet.2005.10.018] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2005] [Revised: 10/11/2005] [Accepted: 10/13/2005] [Indexed: 01/05/2023]
Abstract
N-acetyltransferase (NAT) 2 is an essential polymorphic enzyme involved in the metabolism of various xenobiotics, including potential carcinogens. The individual differences in the NAT2 metabolic capacity are caused by allelic variants of the NAT2 gene which are determined by a pattern of single nucleotide polymorphisms (SNPs) resulting in slow (SA), intermediate (IA) or rapid acetylator (RA) phenotypes. Highly penetrant germline mutations in mismatch repair (MMR) genes are the cause of the disease in hereditary nonpolyposis colorectal cancer (HNPCC). There is no strict correlation between the type of germline mutation in MMR genes and the HNPCC phenotype, but age of tumor onset (AO) in HNPCC has been associated at least in part with different variants in apoptosis-related genes. To clarify the potential modifying role of the NAT2 acetylator status in HNPCC, we performed a multicenter study in 226 individuals with colorectal cancer carrying exclusively pathogenic germline mutations in MSH2 or MLH1. We did not observe any significant difference in the NAT2 acetylator status frequency between HNPCC patients and 107 healthy controls (P=0.156), and between MLH1 and MSH2 mutation carriers (P=0.198). Multivariate Cox regression analysis revealed that male patients had a significantly increased risk to develop CRC compared to females during any interval (P=0.043), while the NAT2 acetylator status (P=0.447) and the mutated gene (MLH1 or MSH2) (P=0.236) were not risk factors for AO. The median AO in HNPCC patients was 39 years in patients with RA as well as with SA status (P=0.347). In MLH1 mutation carriers, the median AO was 38 years in RA and 36 years in SA status patients (P=0.901), whereas in MSH2 mutation carriers, the median AO was 39 years in RA and 42 years in SA status patients (P=0.163). Log-rank test revealed a significantly lower age of CRC onset in male compared to female HNPCC patients (P=0.0442). These data do not support the hypothesis that the NAT2 acetylatorship acts as a modifying factor on AO in HNPCC-associated CRC.
Collapse
Affiliation(s)
- Steffen Pistorius
- Department of Visceral, Thoracic and Vascular Surgery, University of Technology Dresden, Fetscherstr. 74, 01307 Dresden, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Berkhout M, Roelofs HMJ, Friederich P, van Krieken JHJM, Nagengast FM, Peters WHM. Detoxification enzymes in the duodenal mucosa of patients with familial adenomatous polyposis. Br J Surg 2005; 92:754-5. [PMID: 15856485 DOI: 10.1002/bjs.4996] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Unlikely to be involved in duodenal polyposis
Collapse
Affiliation(s)
- M Berkhout
- Department of Gastroenterology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
| | | | | | | | | | | |
Collapse
|